Efficacy of pregabalin in the treatment of generalized anxiety disorder / Robert B. Pohl en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 2 (Abril) . - pp. 151-158 Título : Efficacy of pregabalin in the treatment of generalized anxiety disorder : Double-blind, placebo-controlled comparison of bid versus tid dosing Tipo de documento: texto impreso Autores: Robert B. Pohl, Autor ; Douglas E. Feltner, Autor ; Ronald R. Fieve, Autor Fecha de publicación: 2023 Artículo en la página: pp. 151-158 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos de ansiedad, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a new anxiolytic that acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the α2-δ subunit of voltage-gated calcium channels. The current study evaluated the anxiolytic efficacy of BID versus TID dosing of pregabalin in patients with generalized anxiety disorder. Link: ./index.php?lvl=notice_display&id=30915 [artículo] Efficacy of pregabalin in the treatment of generalized anxiety disorder : Double-blind, placebo-controlled comparison of bid versus tid dosing [texto impreso] / Robert B. Pohl, Autor ; Douglas E. Feltner, Autor ; Ronald R. Fieve, Autor . - 2023 . - pp. 151-158. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 2 (Abril) . - pp. 151-158 Palabras clave: Trastornos de ansiedad, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a new anxiolytic that acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the α2-δ subunit of voltage-gated calcium channels. The current study evaluated the anxiolytic efficacy of BID versus TID dosing of pregabalin in patients with generalized anxiety disorder. Link: ./index.php?lvl=notice_display&id=30915

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder / Atul C. Pande en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 141-149 Título : Efficacy of the novel anxiolytic pregabalin in social anxiety disorder : A placebo-controlled, multicenter study Tipo de documento: texto impreso Autores: Atul C. Pande, Autor ; Douglas E. Feltner, Autor ; James W. Jefferson, Autor Fecha de publicación: 2023 Artículo en la página: pp. 141-149 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Ansiolíticos, Ansiedad, Pregabalina, Trastornos del comportamiento social, Aumento de peso - efectos de medicamentos. Resumen: Pregabalin is a novel compound in the development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pregabalin 150 mg/d, pregabalin 600 mg/d, or placebo. Link: ./index.php?lvl=notice_display&id=30962 [artículo] Efficacy of the novel anxiolytic pregabalin in social anxiety disorder : A placebo-controlled, multicenter study [texto impreso] / Atul C. Pande, Autor ; Douglas E. Feltner, Autor ; James W. Jefferson, Autor . - 2023 . - pp. 141-149. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 141-149 Palabras clave: Ansiolíticos, Ansiedad, Pregabalina, Trastornos del comportamiento social, Aumento de peso - efectos de medicamentos. Resumen: Pregabalin is a novel compound in the development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pregabalin 150 mg/d, pregabalin 600 mg/d, or placebo. Link: ./index.php?lvl=notice_display&id=30962

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder / Douglas E. Feltner en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249 Título : A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder Tipo de documento: texto impreso Autores: Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor Fecha de publicación: 2023 Artículo en la página: pp. 240-249 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. Link: ./index.php?lvl=notice_display&id=31020 [artículo] A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder [texto impreso] / Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor . - 2023 . - pp. 240-249. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249 Palabras clave: Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. Link: ./index.php?lvl=notice_display&id=31020

---

1 (1 - 3 / 3)